Public comment periods — page 4
120 consultations carrying 1,332 signed submissions. Every submission has a declared interest, a secretariat response and a disposition.
Consultations
-
Consultation on the draft safety review of the rodent thyroid C-cell signal observed with glucagon-like peptide-1 receptor agonists and its relevance to humans. The review assesses the mechanistic evidence for a species difference in…
16 submissions -
Consultation on the draft monograph for Selank, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…
8 submissions1 not accepted -
Consultation on the draft monograph for TB-500, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for that…
8 submissions -
Consultation on the print and archival format for Institute documents: what a printed copy must carry so that it remains checkable when detached from the site, and what an archival copy must preserve.
18 submissions4 not accepted -
Consultation on the draft of this scoping review, which registers the question: What randomised human evidence exists for BPC-157 in any indication?
4 submissions -
Consultation on the draft of this intervention review, which registers the question: In adults at elevated cardiovascular risk, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on major adverse…
13 submissions1 not accepted -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and weight effect than semaglutide?
7 submissions1 not accepted -
Consultation on the terms governing the Institute's calculators. The draft states that a calculator implements a published formula, that it holds no user data, and that its output is a computation and not clinical advice.
18 submissions3 not accepted -
Consultation on the third version of the semaglutide monograph. The revision incorporates the cardiovascular outcome evidence from SELECT, reported in the New England Journal of Medicine in 2023, and the kidney outcome evidence from FLOW…
14 submissions1 not accepted -
Consultation on the draft of CEI-MS-06, which specifies the performance a determination must achieve for microbiological quality and states what the resulting figure does not establish. The draft states performance rather than prescribing…
13 submissions2 not accepted -
Consultation on the draft monograph for GHRP-2, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…
7 submissions -
Consultation on the draft of this safety review, which registers the question: What is the incidence of gastrointestinal adverse events and of discontinuation for adverse events with incretin receptor agonists compared with placebo?
12 submissions2 not accepted -
Consultation on the draft monograph for Dulaglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at high certainty and states the basis for that…
11 submissions -
Consultation on the draft monograph for GHK-Cu, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…
7 submissions1 not accepted -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes and chronic kidney disease, what is the effect of a glucagon-like peptide-1 receptor agonist on kidney outcomes?
11 submissions -
Consultation on the structure of the document registry: the identifier scheme, the fields carried for every document, and the way a superseded document is represented. The draft assigns a permanent identifier at first publication and never…
9 submissions1 not accepted -
Consultation on the draft of this safety review, which registers the question: Do incretin-based therapies increase the incidence of acute pancreatitis?
10 submissions3 not accepted -
Consultation on the search-strategy template used across the synthesis series: the databases searched, the structure of the strategy, the handling of registry records without posted results, and the requirement that a strategy be published…
19 submissions2 not accepted -
Consultation on the draft monograph for Semaglutide, oral, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at high certainty and states the basis…
9 submissions1 not accepted -
Consultation on how the Institute should label a programme record it has constructed by grouping trials, as distinct from a programme as defined by its sponsor. The draft proposes a standing notice on every constructed record stating who…
13 submissions3 not accepted
page 4 of 6